NovaGo Therapeutics
Tracked across 1 events · 6 articles · First seen Jul 20, 2026 · Last active Sep 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: NovaGo is the central entity, closing a CHF 24 million Series B round to fund its proof-of-concept study in acute spinal cord injury. This financing strengthens its balance sheet and advances its lead program toward clinical validation.
Jul 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track NovaGo Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard